Literature DB >> 1531211

Increases in tumor response by pentoxifylline alone or in combination with nicotinamide.

I Lee1, J H Kim, S H Levitt, C W Song.   

Abstract

Pentoxifylline (PENTO), a derivative of methylxanthine, has been reported to improve fluidity of red blood cells (RBC), and thus improve the flux of RBC through narrow capillaries. Additionally, PENTO increases 2,3-DPG levels in RBC, thereby increasing the O2 release from RBC. Nicotinamide (NA) has been known to increase tumor blood flow, reducing the hypoxic cell fractions in the tumors. The purpose of this study was to examine the effects of PENTO alone or in combination with NA (PENTO + NA) on the oxygenation and radio-response of FSaII murine fibrosarcomas of mice. We observed a significantly enhanced, radiation-induced growth delay of the FSaII tumors by the treatment of either single or multiple injections of PENTO. The combination of PENTO and NA further delayed the growth of tumors. The TCD50 of control tumors was about 56.6 Gy, whereas that of PENTO + NA treated tumors was about 31.9 Gy. Thus, TCD50 was modified by a factor of 1.8. PENTO + NA exerted no effect on the acute skin damage of C3H mice after local irradiation and the gastrointestinal death after whole body irradiation. However, PENTO + NA slightly increased the bone marrow death as demonstrated by the decrease in LD50(30) from 5.5 Gy to 5.2 Gy. The average pO2 in the saline-treated control group of FSaII tumors was 8 mmHg and it significantly increased to 19 mmHg in the PENTO + NA treated group (p less than 0.001). We concluded that the PENTO + NA treatment increased the radio-response of tumors by improving tumor oxygenation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1531211     DOI: 10.1016/0360-3016(92)90846-a

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  [Regression of Yoshida sarcoma during normoxia and hypoxia after fractionated irradiation].

Authors:  V Strnad; F Kamprad; J Jahns; M Meyer; R Böhme; P Madaj-Sterba; M Kirschner; R Sauer
Journal:  Strahlenther Onkol       Date:  1997-03       Impact factor: 3.621

2.  Transiently hypoxic tumour cell turnover and radiation sensitivity in human tumour xenografts.

Authors:  Brennan J Wadsworth; Che-Min Lee; Kevin L Bennewith
Journal:  Br J Cancer       Date:  2022-01-14       Impact factor: 9.075

Review 3.  Hypoxia and drug resistance.

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

4.  Pentoxifylline treatment of sepsis of premature infants: preliminary clinical observations.

Authors:  R Lauterbach; D Pawlik; B Tomaszczyk; B Cholewa
Journal:  Eur J Pediatr       Date:  1994-09       Impact factor: 3.183

Review 5.  Inhibition of homologous recombination repair with Pentoxifylline targets G2 cells generated by radiotherapy and induces major enhancements of the toxicity of cisplatin and melphalan given after irradiation.

Authors:  Lothar Bohm
Journal:  Radiat Oncol       Date:  2006-05-03       Impact factor: 3.481

6.  Drug-induced alterations in tumour perfusion yield increases in tumour cell radiosensitivity.

Authors:  K L Bennewith; R E Durand
Journal:  Br J Cancer       Date:  2001-11-16       Impact factor: 7.640

Review 7.  The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia.

Authors:  Bernard Gallez
Journal:  Front Pharmacol       Date:  2022-07-15       Impact factor: 5.988

8.  The effects of pentoxifylline on the relative perfusion of tumours growing in three sites in the mouse.

Authors:  P L Sensky; V E Prise; A E Ward; D G Hirst
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

9.  Changes in tumour blood flow, oxygenation and interstitial fluid pressure induced by pentoxifylline.

Authors:  I Lee; Y Boucher; T J Demhartner; R K Jain
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.